CL2024000397A1 - Administración de agentes terapéuticos por vía venosa coronaria retrógrada o sinusal - Google Patents

Administración de agentes terapéuticos por vía venosa coronaria retrógrada o sinusal

Info

Publication number
CL2024000397A1
CL2024000397A1 CL2024000397A CL2024000397A CL2024000397A1 CL 2024000397 A1 CL2024000397 A1 CL 2024000397A1 CL 2024000397 A CL2024000397 A CL 2024000397A CL 2024000397 A CL2024000397 A CL 2024000397A CL 2024000397 A1 CL2024000397 A1 CL 2024000397A1
Authority
CL
Chile
Prior art keywords
administration
therapeutic agents
agents via
coronary venous
via retrograde
Prior art date
Application number
CL2024000397A
Other languages
English (en)
Spanish (es)
Inventor
M Feldman Arthur
Myers Valerie
Bologna Marcia
Original Assignee
Univ Temple
Renovacor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Renovacor Inc filed Critical Univ Temple
Publication of CL2024000397A1 publication Critical patent/CL2024000397A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2024000397A 2021-08-12 2024-02-08 Administración de agentes terapéuticos por vía venosa coronaria retrógrada o sinusal CL2024000397A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163260225P 2021-08-12 2021-08-12
US202163263442P 2021-11-02 2021-11-02
US202263343985P 2022-05-19 2022-05-19

Publications (1)

Publication Number Publication Date
CL2024000397A1 true CL2024000397A1 (es) 2024-08-30

Family

ID=85201030

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000397A CL2024000397A1 (es) 2021-08-12 2024-02-08 Administración de agentes terapéuticos por vía venosa coronaria retrógrada o sinusal

Country Status (10)

Country Link
US (1) US20260069719A1 (https=)
EP (1) EP4384269A4 (https=)
JP (1) JP2024529170A (https=)
KR (1) KR20240063110A (https=)
AU (1) AU2022325237A1 (https=)
CA (1) CA3228581A1 (https=)
CL (1) CL2024000397A1 (https=)
IL (1) IL310763A (https=)
MX (1) MX2024001939A (https=)
WO (1) WO2023019272A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117010A2 (en) 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
WO2024229259A1 (en) * 2023-05-02 2024-11-07 Research Institute At Nationwide Children's Hospital Gene therapy for treatment of protein misfolding diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117010A2 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 as a target for therapy of heart failure
SG11201803934YA (en) * 2015-11-11 2018-06-28 Intrexon Corp Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies

Also Published As

Publication number Publication date
AU2022325237A1 (en) 2024-03-21
IL310763A (en) 2024-04-01
AU2022325237A2 (en) 2024-03-28
EP4384269A4 (en) 2026-03-18
KR20240063110A (ko) 2024-05-10
JP2024529170A (ja) 2024-08-01
EP4384269A1 (en) 2024-06-19
US20260069719A1 (en) 2026-03-12
CA3228581A1 (en) 2023-02-16
MX2024001939A (es) 2024-07-10
WO2023019272A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
CL2024000397A1 (es) Administración de agentes terapéuticos por vía venosa coronaria retrógrada o sinusal
MX2022000143A (es) Metodos novedosos.
ECSP21051833A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
RU2747124C2 (ru) Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина
BR112013004698A2 (pt) composições farmacêuticas compreendendo derivados de poh
ECSP22049008A (es) M?todos de tratamiento del c?ncer de pulm?n de c?lulas peque?as con formulaciones de lurbinectedina
AR119158A1 (es) Tratamientos de angioedema hereditario
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
SA520410975B1 (ar) تركيبات طويلة المفعول
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
PE20190351A1 (es) Agente terapeutico del sindrome de hunter y metodo de tratamiento
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
CL2025000279A1 (es) Arn para prevenir o tratar tuberculosis
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2023000439A (es) Formulaciones a largo plazo.
CO2020001322A2 (es) Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
MX2018016361A (es) Derivado de piranocromenil fenol opticamente activo y composición farmacéutica que comprende el mismo.
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
PE20240051A1 (es) Metodos para el tratamiento del cancer con administracion subcutanea de anticuerpos anti-pd1
CO2021011319A2 (es) Tratamientos combinados para su uso en el tratamiento del cáncer
WO2014145199A8 (en) Retrograde delivery of sdf-1 for treatment of myocardial infarction
GEAP202416526A (en) Treatment of major depressive disorder